ArticleDEN open2026
Efficacy and Safety of Duodenal Stenting for Malignant Gastric Outlet Obstruction: Insights From a 15-year Single-Center Experience.
Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Endoscopic ultrasonography-guided gastroenterostomy versus conventional approaches for cancer-related malignant gastrointestinal outlet obstruction: a meta-analysis with trial sequential analysis.Surgical endoscopy · 2026Pooled it
- Efficacy and Safety of Duodenal Stenting for Malignant Gastric Outlet Obstruction: Insights From a 15-year Single-Center Experience.DEN open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Endoscopic duodenal stent (DS) placement has become a primary palliative approach for malignant gastric outlet obstruction (MGOO), offering minimally invasive symptom relief. However, complications and risk factors for stent dysfunction and prognostic indicators of survival are not fully elucidated. Methods: We retrospectively analyzed 114 patients who underwent initial DS placement for MGOO at Kyushu University Hospital between January 2010 and October 2024. Clinical outcomes, stent patency, and survival predictors were analyzed. The primary endpoint was stent patency; overall survival (OS) was a secondary endpoint. Results: Pancreatic cancer was the most common underlying malignancy (77.2%). Technical and clinical success rates were 99.1% and 84.1%, respectively; the overall clinical success rate reached 91.2% after additional stenting in initially unsuccessful cases. Adverse events occurred in 12.3% of patients. Among 104 patients with overall clinical success, 18 patients (17.3%) experienced stent dysfunction. Median stent patency and OS were 14.8 and 2.8 months, respectively. Pre-existing biliary stricture and stent placement across the pylorus were significantly associated with reduced stent patency. High neutrophil-to-lymphocyte ratio predicted poorer survival, whereas type III stenosis and post-stenting chemotherapy were linked to improved survival. No significant differences in outcomes were observed between early and late treatment periods. Reintervention with DS was safe and effective, and 93.3% of patients maintained GOO control with DS alone. Conclusions: Duodenal stenting is a safe and effective palliative intervention for MGOO. Incorporating inflammation-based biomarkers and individualized treatment strategies can help optimize patient selection and improve survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.